Paola Allavena

Dr. Paola Allavena


Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2008 in Nature
Verified
Journal Article
Closed access
Alberto MantovaniAlberto Mantovani
Alberto Mantovani
PAPaola Allavena
Paola Allavena
ASAntonio Sica
Antonio Sica
FBFrances Balkwill
Frances Balkwill

1 December 2004 in Trends in Immunology
Verified
Journal Article
Closed access
Alberto MantovaniAlberto Mantovani
Alberto Mantovani
ASA Sica
A Sica
SSSilvano Sozzani
Silvano Sozzani
PAPaola Allavena
Paola Allavena
AVA Vecchi
A Vecchi
MLMassimo Locati
Massimo Locati

1 November 2002 in Trends in Immunology
Verified
Journal Article
Closed access
Alberto MantovaniAlberto Mantovani
Alberto Mantovani
SSSilvano Sozzani
Silvano Sozzani
MLMassimo Locati
Massimo Locati
PAPaola Allavena
Paola Allavena
ASA Sica
A Sica

24 January 2017 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
Alberto MantovaniAlberto Mantovani
Alberto Mantovani
FMFederica Marchesi
Federica Marchesi
AMAlberto Malesci
Alberto Malesci
LLLuigi Laghi
Luigi Laghi
PAPaola Allavena
Paola Allavena

25 May 2009 in Carcinogenesis
Verified
Journal Article
Closed access
FCF. Colotta
F. Colotta
PAPaola Allavena
Paola Allavena
ASA. Sica
A. Sica
CGCecilia Garlanda
Cecilia Garlanda
Alberto MantovaniAlberto Mantovani
Alberto Mantovani
Inflammatory conditions in selected organs increase the risk of cancer. An inflammatory component is present also in the microenvironment of tumors that are not epidemiologically related to inflammation. Recent studies have begun to unravel molecular pathways linking inflammation and cancer. In the tumor microenvironment, smoldering inflammation contributes to proliferation and survival of malignant cells, angiogenesis, metastasis, subversion of adaptive immunity, reduced response to hormones and chemotherapeutic agents. Recent data suggest that an additional mechanism involved in cancer-related inflammation (CRI) is induction of genetic instability by inflammatory mediators, leading to accumulation of random genetic alterations in cancer cells. In a seminal contribution, Hanahan and Weinberg [(2000) Cell, 100, 57-70] identified the six hallmarks of cancer. We surmise that CRI represents the seventh hallmark.

5 January 1998 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
RBRaffaella Bonecchi
Raffaella Bonecchi
GBGiancarlo Bianchi
Giancarlo Bianchi
PBPaola Panina Bordignon
Paola Panina Bordignon
DDDaniele D'Ambrosio
Daniele D'Ambrosio
RLRosmarie Lang
Rosmarie Lang
FSFrancesco Sinigaglia
Francesco Sinigaglia
T helper cells type 1 (Th1s) that produce interferon-γ predominantly mediate cellular immune responses and are involved in the development of chronic inflammatory conditions, whereas Th2s which produce large amounts of IL-4 and IL-5 upregulate IgE production and are prominent in the pathogenesis of allergic diseases. The precise factors determining whether Th1- or Th2-mediated immune responses preferentially occur at a peripheral site of antigen exposure are largely unknown. Chemokines, a superfamily of polypeptide mediators, are a key component of the leukocyte recruitment process. Here we report that among four CXC (CXCR1-4) and five CC (CCR1-5) chemokine receptors analyzed, CXCR3 and CCR5 are preferentially expressed in human Th1s. In contrast, Th2s preferentially express CCR4 and, to a lesser extent, CCR3. In agreement with the differential chemokine receptor expression, Th1s and Th2s selectively migrate in response to the corresponding chemokines. The differential expression of chemokine receptors may dictate, to a large extent, the migration and tissue homing of Th1s and Th2s. It may also determine different susceptibility of Th1s and Th2s to human immunodeficiency virus strains using different fusion coreceptors.